Scoreboard / UTHR
United Therapeutics Corporation UTHR
Issue No. 15 pick · October 2, 2026 · Updated October 16, 2026
Setup Snapshot
The Setup in One Card
How UTHR moved and the catalyst behind the move, from its Issue No. 15 write-up. It is not on the current Scoreboard, so it carries no Friday Five Score this week.
Issue No. 15
Original Pick
Sector Trend
Leadingup 5.4 percent
Covered In
Issue No. 15 · October 2, 2026
Catalyst
Patent RulingA Delaware district court found on September 30 that a competitor infringes two claims of the inhaled treprostinil patent.
Return measured from the Thursday, September 24 close to the Thursday, October 1 close, the week it appeared in Issue No. 15.
Why It Moved
The Story Behind the Move
Catalyst
A Delaware district court found on September 30 that a competitor infringes two claims of the inhaled treprostinil patent.
Why It Mattered
A court ruling is the most literal form of proof a market can be handed, and the alternatives rule out cleanly: the Food and Drug Administration filing acceptance and the accelerated buyback that also circulated were both announced in early September, before this measurement window opened. A 21 percent move in a sector that fell 2.16 percent is about as company specific as a week gets.
Risk Note
A district court opinion is not a final judgment. The remedy has not been set, whether the Food and Drug Administration is actually instructed to withdraw the competing approval has not been decided, and an appeal is available. The load bearing sentence is the company stating what it believes it is entitled to, which is a litigation position rather than an order.
Reader Takeaway
Legal outcomes get priced as if they are final the day they are announced, and they are usually one step in a longer process. Read what the court actually decided, then read separately what the company says that entitles it to.
Continue the Research
Put UTHR Back in Context
The stock page is one piece of the weekly research. Continue with the original issue, the full public ranking, or the method behind the analysis.
This page is for educational and informational purposes only. It is not financial advice, investment advice, or a recommendation to buy or sell any security.